# To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N

Source: https://onco.cc/trials/nct05442060/  
OnCo record `nct05442060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by OBI Pharma, Inc, now recruiting.

## Summary

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05442060 by OBI Pharma, Inc, with 60 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-12-31. Interventions recorded: 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily). Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05442060
- Phase: 2
- Setting: A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: OBI Pharma, Inc
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05442060: https://clinicaltrials.gov/study/NCT05442060

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Erlotinib](https://onco.cc/drugs/erlotinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05442060.json